Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43026 (
lipopolysaccharide
)
62,215
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
6-(methylsulfinyl)hexyl isothiocyanate (6-MITC) is a bioactive compound extracted from a typical Japanese spice, wasabi (Wasabia japonica (Miq.) Matsumura). In the present study, we found that 6-MITC suppressed the expression of cyclooxygenase-2 (COX-2) induced by
lipopolysaccharide
(
LPS
), interferon-gamma (IFN-gamma), but did not suppress that induced by 12-O-tetradecanoylphorbol-13-acetate (TPA), in murine macrophage RAW264. Molecular mechanisms were investigated by targeting the transcriptional factors including activator protein-1 (AP-1),
CCAAT/enhancer-binding protein delta
(C/EBPdelta), CRE-binding protein (CREB) and nuclear factor kappaB (NF-kappaB), which bind to the core element of COX-2 promoter.
LPS
induced activation of all of these factors and 6-MITC suppressed
LPS
-induced activation of AP-1, C/EBPdelta, CREB, but not NF-kappaB. IFN-gamma did not induce any activation of these factors, but 6-MITC suppressed IFN-gamma-induced COX-2 expression, suggesting that the upstream region of the core element is linked for this suppression. Finally, TPA stimulated the activation of CREB and AP-1, but 6-MITC did not block TPA-induced COX-2 expression. These results suggest that
LPS
, IFN-gamma and TPA regulate COX-2 expression through different mechanisms, and 6-MITC acts as a potent inhibitor of COX-2 expression induced by
LPS
or IFN-gamma.
...
PMID:Effects of 6-(methylsulfinyl)hexyl isothiocyanate on cyclooxygenase-2 expression induced by lipopolysaccharide, interferon-gamma and 12-O-tetradecanoylphorbol-13-acetate. 1714 3
The transcription factor CCAAT/enhancer binding protein delta (
C/EBP delta
) regulates transcription of genes that play important roles in glial activation. Previous studies have shown the astroglial expression of
C/EBP delta
but the microglial expression of
C/EBP delta
remains virtually unexplored, with the exception of two microarray studies. In this report, using murine primary cultures and BV2 cells we clearly demonstrate that
C/EBP delta
is expressed by microglia and it is upregulated in microglial activation. Lipopolysaccharide upregulates
C/EBP delta
both in microglia and in astrocytes. This effect is time-dependent, with a maximum effect at 3 hr at mRNA level and at 4-8 hr at protein level, and concentration-dependent, with a maximum effect at 100 ng/mL. The
lipopolysaccharide
-induced
C/EBP delta
upregulation in BV2 microglia is mimicked by agonists of the toll-like receptors 2, 3 and 9 and can be prevented by an inhibitor of extracellular signal-regulated kinase activation.
C/EBP delta
from activated BV2 microglia binds to the cyclooxygenase-2 promoter and forms complexes with C/EBP beta isoforms. These results point to
C/EBP delta
as a putative key regulator of proinflammatory gene expression in microglial activation.
...
PMID:CCAAT/enhancer binding protein delta in microglial activation. 1990 86
Cyclooxygenase 2 (COX-2) is an important inflammatory factor. Previous studies have indicated that COX-2 is induced with
lipopolysaccharide
(
LPS
) treatment. Here, we found that an inhibitor of histone deacetylase (HDAC), trichostatin A (TSA), cannot repress
LPS
-induced COX-2 but it increased the COX-2 level in RAW264.7 cells. We found no significant difference in NF-kappaB activation and ERK1/2 phosphorylation, but
LPS
-induced
C/EBP delta
expression was completely abolished after TSA treatment of
LPS
-treated cells. Interesting, reporter assay of
C/EBP delta
promoter revealed that Sp1-binding site is important. Although there was no alteration in c-Jun levels, but the phosphorylation of c-Jun at its C-terminus was increased dramatically. A DNA-associated protein assay (DAPA) and chromatin immunoprecipitation assay (ChIP) indicated that c-Jun was recruited via Sp1 to the promoter of
C/EBP delta
after
LPS
treatment; this recruitment of c-Jun was repressed by TSA.
C/EBP delta
inhibition by TSA resulted in increased binding of C/EBP alpha and C/EBP beta to the COX-2 promoter. Therefore, TSA has a positive effect on
LPS
-induced COX-2 since it decreases the
C/EBP delta
level by reducing c-Jun recruitment by Sp1 to the
C/EBP delta
promoter, resulting in increased the recruitment of C/EBP alpha and C/EBP beta to the COX-2 promoter.
...
PMID:Inhibition of LPS-induced C/EBP delta by trichostatin A has a positive effect on LPS-induced cyclooxygenase 2 expression in RAW264.7 cells. 2050 44
<< Previous
1
2